Contraception
Volume 79, Issue 6 , Pages 456-462, June 2009

Two routes of administration for misoprostol in the treatment of incomplete abortion: a randomized clinical trial

  • Ayisha Diop

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 448 1230; fax: +1 212 448 1260.
  • ,
  • Sheila Raghavan

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA
  • ,
  • Jean-Pierre Rakotovao

      Affiliations

    • Befelatanana Maternity Centre, 101 Antananarivo, Madagascar
  • ,
  • Rodica Comendant

      Affiliations

    • Municipal Clinical Hospital No. 1, 2001 Chisinau, Moldova
  • ,
  • Paul D. Blumenthal

      Affiliations

    • Stanford University Medical Center, Palo Alto, CA 94305, USA
  • ,
  • Beverly Winikoff

      Affiliations

    • Gynuity Health Projects, New York, NY 10010, USA

Received 13 June 2008; received in revised form 26 November 2008; accepted 27 November 2008. published online 29 January 2009.

Abstract 

Background

This study was conducted to compare the safety, effectiveness and acceptability of 400 mcg sublingual misoprostol and 600 mcg oral misoprostol for treatment of incomplete abortion.

Study Design

We used an open-label randomized controlled trial conducted from July 2005 to August 2006 in a large tertiary level maternity hospital in Antananarivo, Madagascar, and a large tertiary level hospital in Chisinau, Moldova. Three hundred consenting women seeking treatment for clinically diagnosed incomplete abortion with uterine size ≤12 weeks since last menstrual period were randomized to misoprostol either 600 mcg orally or 400 mcg sublingually. The primary outcome measure was the complete resolution of clinical signs and symptoms of incomplete abortion without need for surgical intervention. Women were seen for follow-up on Day 7 and, if necessary, on Day 14 to assess abortion status. The study was powered to detect a 7% difference in efficacy with a total of 142 women required in each arm.

Results

Efficacy rates were 94.6% and 94.5%, for the oral and sublingual routes, respectively (RR: 1.00, 95% CI=0.95–1.06, p=.98). At 1 week follow-up, more than 80% of women had completed abortions (77.8% oral and 84.8% sublingual, p=.12). Mean pain scores were 2.95 and 3.04, respectively, for the oral and sublingual groups. Side effects included abdominal pain, bleeding, headaches and dizziness/weakness with no differences reported between the two groups. Acceptability and satisfaction were high for both routes and women indicated a preference for medical versus surgical treatment if ever needed in the future.

Conclusions

Both treatment regimens were very effective. Four hundred micrograms of sublingual misoprostol and 600 mcg oral misoprostol appear to have similar safety and effectiveness profiles when used for the treatment of incomplete abortion. A lower 400-mcg misoprostol dose may provide an alternative treatment option as well as have potential benefits in terms of cost.

Keywords: Misoprostol, Sublingual, Incomplete abortion, Postabortion care

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was made possible by an anonymous donor.

PII: S0010-7824(08)00545-3

doi:10.1016/j.contraception.2008.11.016

Contraception
Volume 79, Issue 6 , Pages 456-462, June 2009